Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 244 participants.
Also called NCT01414166
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 244 participants
- Sponsor
- Registry
-
NCT01414166 -
CTRI/2012/08/002873
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01414166. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-03-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
- Condition
- Dyslipidemia
- Intervention (Drug)
- ERN/LRPT
- Intervention (Drug)
- placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01414166- Content hash
e3b85927bc5cf48e916dc7c07f51e13067c908e37d3e7f0df353da521f42b97e